ArticleCureus2026
Longitudinal Assessment of Chest Computed Tomographic Findings After COVID-19 Infection.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe long-term evolution of fibrotic-like changes following moderate-to-severe COVID-19 pneumonia remains unclear. This study aimed to characterize the temporal progression of these abnormalities over a 12-month period.
methodsThis study was conducted as an ancillary analysis of a previously reported multicenter prospective observational study. From September 2020 to September 2021, we enrolled hospitalized adults (≥20 years old) with polymerase chain reaction- or antigen-confirmed COVID-19 classified as moderate or severe. A total of 83 patients who underwent chest CT at both admission and 12 months were included. All CT scans were independently reviewed by two board-certified radiologists. Fibrotic-like changes and CT severity scores (CTSS) were assessed at admission and at 3-, 6-, 9-, and 12-month follow-up. Clinical variables associated with fibrotic-like changes were analyzed.
resultsFibrotic-like changes were present in 18/83 (21.7%) patients at admission and increased to 39/83 (47.0%) patients at 12 months. Their presence at admission was associated with older age, whereas their presence at 12 months was associated with older age and longer length of hospital stay. The prevalence of fibrotic-like changes increased significantly within the first three months (p<0.001) and remained stable thereafter. CTSS also increased significantly during the first three months (p=0.01), without further progression.
conclusionFibrotic-like lung changes after COVID-19 pneumonia tend to progress mainly during the early post-hospitalization phase and stabilize by three months, with no substantial subsequent deterioration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.